Concerned About Unsustainable Cancer Drug Prices? Here's An Idea
A group of leading researchers are suggesting that using academic centers to de-risk cancer drug discovery could tackle the problem of 'unsustainable drug prices'.
You may also be interested in...
A QuintilesIMS Institute study of global oncology trends illustrates the benefits and downside of therapeutic advances – more therapeutic options with better targeting, but also significantly higher complexity in setting a therapeutic course, which is complicated by rising costs.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.